CXCL10 and acute respiratory distress syndrome: While comparing the immunopathology of acute respiratory distress syndrome (ARDS) between patients with COVID-19 and non-COVID-19, Hue S et al. found a unique “chemokine signature” characterized by elevated serum GM-CSF and C-X-C motif chemokine ligand 10 (CXCL10)/Interferon gamma-induced protein 10 (IP-10) levels in a subset of COVID-19 patients who lost survival within 28 days of SARS-CoV-2 infections (Hue et al. 2020).